StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) stock

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.58−0.17 (-6.18%)

Close on Nov 17, 2026Market cap $104.48MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$104.48M
P/E ratio
–
Price to sales
–
Price to book
0.61
Dividend yield
–
Free cash flow yield
-45.81%

Fundamentals

Net income
-$58.71M
EPS, diluted
-$3.50
Free cash flow
-$47.86M
Book value per share
$3.45
Diluted shares
50M

Trading

Next earnings
Mar 11, 2027 (estimated, after the close)
Previous close
$2.75
Open
$2.74
Day's range
$2.50 – $2.81
Volume
228,165
Average volume (20 days)
409,074
Index membership
Russell 2000 (since Jun 2026)
52-week range
$2.01 – $5.38
RSI (14 days)
45.7
Volatility (1 year)
73.3%
Relative volume
0.84×

On 2 of our idea lists: Net-nets, More cash than they're worth

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodOKURS&P 500DifferenceOKUR per yearS&P 500 per year
1 month+22.9%-4.0%+26.9 pts
3 months-37.2%-5.0%−32.3 pts
Year to date-11.0%+8.2%−19.3 pts
1 year-18.4%+11.2%−29.6 pts
3 years-96.2%+68.5%−164.7 pts-66.3%+19.0%
5 years-96.8%+67.3%−164.1 pts-49.9%+10.8%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$62.14M

Net income

-$58.71M

EPS, diluted

-$3.50

Free cash flow

-$47.86M
Reported periodTrailing twelve months

Press releases

Releases OnKure Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About OnKure Therapeutics

Pharmaceutical Preparations

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers and other diseases driven by biologically validated mutations. The company uses a structure-based drug design platform combining medicinal chemistry, x-ray crystallography, and computational chemistry to create small molecule therapies that target mutated proteins while sparing wild-type enzymes. Its lead product candidate is OKI-219, an oral selective inhibitor of PI3Kα H1047R being evaluated in Phase 1 clinical trials for advanced breast cancer and other solid tumors. OnKure also pursues discovery programs targeting other PI3Kα mutations and vascular malformations, designing its therapies for patients with genetically defined oncogenic alterations.

Company profile, executives and history

OnKure Therapeutics stock: common questions

What is OnKure Therapeutics's stock price?

OKUR closed at $2.58 on Nov 17, 2026, down 6.18% on the day. Over the past 52 weeks it traded between $2.01 and $5.38.

What is OnKure Therapeutics's market cap?

OnKure Therapeutics was worth $104.48M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is OKUR's P/E ratio?

OnKure Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.50), so it has no meaningful P/E ratio.

Does OnKure Therapeutics pay a dividend?

No. OnKure Therapeutics has not paid a cash dividend over the last twelve months.

When does OnKure Therapeutics report earnings next?

OnKure Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has OKUR stock performed over the past year?

Including dividends, OKUR returned -18.4% over the past year, against +11.2% for the S&P 500.

How many OKUR shares are sold short?

1M shares were sold short at the latest FINRA report, 4.86% of the float, or 4.2 days of average trading volume.

Who are OnKure Therapeutics's competitors?

Companies most similar to OnKure Therapeutics by business, industry and size include KURA, PRLD, NRIX, APRE, BBOT.

See a number that looks wrong?